Loading...
XSTOGENO
Market cap144mUSD
Dec 23, Last price  
24.55SEK
1D
-1.60%
1Q
6.97%
Jan 2017
862.75%
IPO
-49.84%
Name

Genovis AB

Chart & Performance

D1W1MN
XSTO:GENO chart
P/E
26.13
P/S
10.16
EPS
0.94
Div Yield, %
0.00%
Shrs. gr., 5y
1.11%
Rev. gr., 5y
35.56%
Revenues
158m
+54.54%
379,653986,1781,596,0192,856,0836,080,8738,912,0938,252,06413,268,50118,541,94122,867,26634,567,98060,549,14161,029,72193,017,543102,386,899158,232,000
Net income
62m
+449.55%
-27,149,579-17,558,226-11,291,508-13,607,963-19,915,127-15,852,513-22,048,663-19,905,623-15,031,013-7,948,532-1,710,3819,551,5766,445,90224,777,38511,191,00061,500,000
CFO
68m
P
-16,760,756-13,695,153-10,484,825-12,149,160-14,847,903-12,467,813-22,192,335-16,117,301-16,075,111-8,355,087-1,249,59513,125,5533,755,19345,918,901-927,94767,752,000
Earnings
May 15, 2025

Profile

Genovis AB (publ.) designs, develops, and sells tools for development of drugs for customers in the pharmaceutical and medical device industries. The company offers FabALACTICA, a cysteine protease that digests human IgG1; FabRICATOR, an enzyme that primarily digests the hinge region of IgG; and FabRICATOR Z, an enzyme for the digestion of mouse IgG2a and IgG3, as well as for generating a homogenous pool of F(ab')2 and Fc fragments. It also provides FabULOUS (SpeB), an enzyme for the digestion of IgG in the hinge region; and GingisKHAN, a cysteine protease that digests human IgG1 at a specific site above the hinge. In addition, the company offers GingisREX, a cysteine protease that specifically digests peptide bonds C-terminally to arginine residues; and IgGZERO (EndoS), an endoglycosidase from Streptococcus pyogenes that specifically hydrolyzes N-linked glycans in the Fc-region of native IgG. Further, it provides IgGZERO LE, an endoglycosidase acting on complex type N-glycans from Streptococcus pyogenes; deGlycIT, an IgGZERO (EndoS) enzyme for agarose beads for deglycosylation of Fc-glycans; GlycINATOR an endoglycosidase from Streptococcus pyogenes that hydrolyzes the all glycoforms structure; and GlycINATOR (EndoS2), an endoglycosidase from Streptococcus pyogenes that specifically hydrolyzes glycans at the Fc glycosylation site of IgG. Additionally, the company offers GlyCLICK, a site-specific conjugation technology used for IgG on enzymatic remodeling of the Fc glycans and click chemistry; SialEXO, a sialidase product for the removal and analysis of sialic acids; enzymes for O-glycans; and antibody fragmentation services, as well as operates online store for its products. It serves pharmaceutical and biotech, contract research, and contract manufacturing companies in Sweden, Europe, North America, and Asia. The company has a collaboration with Waters Corporation. Genovis AB (publ.) was founded in 1999 and is based in Lund, Sweden.
IPO date
Nov 11, 2005
Employees
38
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
158,232
54.54%
102,387
10.07%
93,018
52.41%
Cost of revenue
15,160
15,018
33,695
Unusual Expense (Income)
NOPBT
143,072
87,369
59,323
NOPBT Margin
90.42%
85.33%
63.78%
Operating Taxes
(6,650)
(3,195)
(174)
Tax Rate
NOPAT
149,722
90,564
59,496
Net income
61,500
449.55%
11,191
-54.83%
24,777
284.39%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
4,513
2,885
1,708
Long-term debt
154,129
11,761
3,955
Deferred revenue
(2,425)
Other long-term liabilities
2,425
1
Net debt
35,381
(58,273)
(75,729)
Cash flow
Cash from operating activities
67,752
(928)
45,919
CAPEX
(10,440)
(3,825)
(4,491)
Cash from investing activities
(12,808)
(3,825)
(4,491)
Cash from financing activities
(4,513)
(3,732)
(4,230)
FCF
70,231
70,337
74,947
Balance
Cash
123,261
72,830
81,315
Long term investments
89
77
Excess cash
115,349
67,800
76,741
Stockholders' equity
(24,845)
(88,981)
(99,212)
Invested Capital
294,976
221,957
216,037
ROIC
57.93%
41.35%
27.43%
ROCE
52.57%
64.53%
49.76%
EV
Common stock shares outstanding
65,466
65,466
65,466
Price
52.00
13.17%
45.95
-37.05%
73.00
131.75%
Market cap
3,404,217
13.17%
3,008,150
-37.05%
4,778,997
133.08%
EV
3,439,598
2,950,898
4,705,717
EBITDA
152,794
94,000
65,094
EV/EBITDA
22.51
31.39
72.29
Interest
2,264
14,495
Interest/NOPBT
1.58%
16.59%